Sunshine Biopharma signs research agreement with Jewish General Hospital for Adva-27a anticancer compound

Sunshine Biopharma Inc.

3-year agreement to advance Adva-27a through IND-enabling studies; JGH paid fair market value for services.
Sunshine retains exclusive ownership of all improvements and research results; JGH receives 3% royalty for 20 years on net revenues from IP.
Research led by Dr. Gerald Batist, Head of Oncology at JGH and Director of the McGill Centre for Translational Research in Cancer.
If results are conclusive, parties will negotiate terms to conduct a Phase I clinical trial.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sunshine Biopharma Inc. entered into Research Agreement with Sir Mortimer B. Davis Jewish General Hospital valued at 3% royalty (effective 2023-02-07).

Action: entry
Agreement: collaboration
Counterparty: Sir Mortimer B. Davis Jewish General Hospital
Value: 3% royalty
Effective: 2023-02-07

Exact text from the filing

On February 7, 2023, Sunshine Biopharma, Inc. (the “Company”) received a duly executed research agreement (the “Research Agreement”) with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada (“JGH”) in connection with the Company’s Adva-27a anticancer compound.

View on SEC.gov

Browse all material agreements →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-000716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.